Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia

BACKGROUND: Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS: Adult refractory ITP patients (<30,000...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Res
Main Authors: Kim, Yeo-Kyeoung, Lee, Seung-Sin, Jeong, Sung-Hoon, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4377333/
https://ncbi.nlm.nih.gov/pubmed/25830126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2015.50.1.19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados